Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Zhejiang Huahai Pharmaceutical Co Ltd
Other Operating Expenses
Zhejiang Huahai Pharmaceutical Co Ltd
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
|
Other Operating Expenses
-¥19.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Operating Expenses
¥1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
155%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Operating Expenses
¥443.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Operating Expenses
¥49.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-8%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Other Operating Expenses
¥245.1m
|
CAGR 3-Years
14%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Operating Expenses
¥43.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Zhejiang Huahai Pharmaceutical Co Ltd
Glance View
Zhejiang Huahai Pharmaceutical Co., Ltd., nestled in the vibrant economic landscape of China, has crafted a reputation as a pioneering force in the pharmaceutical industry. The company began its journey with a modest ambition: to establish itself as a reliable provider of Active Pharmaceutical Ingredients (APIs). Over the years, Huahai has broadened its horizons beyond APIs, expanding into the realm of finished dosage forms. This strategic diversification has enabled the company to control the entire value chain—from manufacturing raw pharmaceutical compounds to delivering final medicines ready for consumption. This integrated approach not only enhances quality control but also fortifies their market presence globally, allowing Huahai to cement its status as a formidable player in pharmaceutical exports. What sets Zhejiang Huahai apart is its steadfast commitment to innovation and compliance with international standards. The company channels considerable resources into research and development, focusing on therapeutic areas such as cardiovascular and central nervous system disorders. This devotion to R&D not only fuels the pipeline of new products but also enhances profitability by ensuring a steady stream of high-demand medications. Furthermore, Huahai's strategic partnerships with global pharmaceutical giants shape a dual-edged strategy of market expansion and shared expertise. By working closely with partners worldwide, Huahai ensures that its products remain at the cutting edge of medical advancements while maintaining regulatory compliance in diverse markets. This approach is what powers Huahai's steady revenue growth and robust competitive edge in the ever-evolving pharmaceutical sector.
See Also
What is Zhejiang Huahai Pharmaceutical Co Ltd's Other Operating Expenses?
Other Operating Expenses
-19.7m
CNY
Based on the financial report for Sep 30, 2025, Zhejiang Huahai Pharmaceutical Co Ltd's Other Operating Expenses amounts to -19.7m CNY.
What is Zhejiang Huahai Pharmaceutical Co Ltd's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 10Y
0%